ArticleComputational and structural biotechnology journal2025
Mathematical strategies for predicting resistant subpopulations from scRNAseq data of a PANC-1 3D tissue model: Insight into gemcitabine resistance and TGFB1-induced invasion and EMT.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DataXflowGen for GenAI-driven model generation.Scientific reports · 2026Article
- Cell Population Dynamics Informed by Cell-Cycle Regulation: A Deterministic Modeling Toolkit.Computational and structural biotechnology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma is characterized by high levels of chemoresistance and aggressive progression of the disease, which is a major challenge for effective treatment. Conventional 2D cultures capture therapy resistance only to a limited extent, whereas 3D cultures may better reflect relevant conditions. Methods: We established 3D PANC-1 tissue models based on a decellularized porcine jejunum with niche-specific drug response to gemcitabine (GEM) treatment. TGFB1 induced invasion and further drug resistance. Thus, we performed scRNA-seq after treatment with GEM, TGFB1 stimulation, or both. Data were analyzed using standard approaches and a novel mutual-information-based machine learning framework (gSELECT). Candidate genes were further evaluated through enrichment and survival analyses.Additionally, we present a novel mathematical approach as proof of concept for analyzing differences in gene expression between groups seemingly similar with respect to a projection such as t-SNE or UMAP (e.g., GEM-treated and untreated cells). For this, we stratified control cells by similarity to GEM-treated survivors, yielding predicted-resistant and predicted-sensitive subgroups for downstream analysis. Results: Pre-analysis using machine learning and comparative analyses of single-cell RNA sequencing data showed only minor differences in gene expression in response to GEM treatment, whereas TGFB1 induced an invasive phenotype characterized by EMT-related transcriptional changes, including downregulation of cytokeratins.Laboratory experiments showed that ∼75 % of PANC-1 cells survived GEM in 3D, indicating intrinsic resistance. Our mathematical approach using machine learning predicted a GEM-sensitive subpopulation consistent with these findings. Comparative analyses revealed mutual information (MI) genes distinguishing sensitive from resistant cells, several of which were supported by literature and survival data. Conclusion: Computational analysis of scRNA-seq data from 3D-cultured PANC-1 cells provides a useful framework for studying treatment effects. The potential relevance of the identified MI genes is supported by further
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.